News

MINIject on best-in-class trajectory at Innovation Summit

CEO Michel Vanbrabant presented to an audience of institutional and strategic investors at the Innovation Summit Dublin on 13-15 April.

STAR-II promising results in Ophthalmology Times

The six and 12-month results from the STAR-II trial on MINIjectTM have been reported in the latest issue of Ophthalmology Times.

iSTAR Medical 2021 roadmap at BioCapital Europe

CEO Michel Vanbrabant will present the company’s latest positive developments and an ambitious 2021 roadmap for iSTAR Medical at the Biocapital Europe meeting on 11 March.

MINIject STAR-II 12-month trial results at AGS

The 12-month results from the European STAR-II trial of iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM will be presented at the American Glaucoma Society (AGS) meeting.

MINIject in Ophthalmology Times Europe

An article in Ophthalmology Times Europe outlines how the suprachoroidal space promises to become a feasible route to effectively reduce intraocular pressure (IOP) in patients with glaucoma, thanks to iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM.